$5.950
+0.030 (+0.51%)Al cierre
- High
- 6.000
- Open
- 5.950
- VWAP
- 5.78
- Vol
- 52.55K
- Mkt Cap
- 4.27M
- Low
- 5.400
- Amount
- 303.90K
- EV/EBITDA, TTM
- 0.24
Axe Compute Inc., formerly Predictive Oncology Inc., is engaged in using artificial intelligence (AI) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy when a tumor sample responds to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Through AI, it uses its proprietary biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of drug development. The Company offers a suite of solutions for oncology drug development from early discovery to clinical trials.
Métricas de valoración
Cronología de eventos
Noticias
9.501-15BenzingaRF Industries Reports $22.7M Q4 Sales, Shares Surge 21.4%
2.012-08NASDAQ.COMHealthcare Stocks Surge in After-Hours Trading: KYMR, OCUL, POAI Lead the Gains
4.509-29BenzingaNasdaq Soars 150 Points as US Pending Home Sales Increase
8.509-29SeekingAlphaPredictive Oncology Reveals $344 Million in Private Placements
2.009-28TipRanksStock Splits Scheduled for This Week (September 29 to October 3) – Keep Your Investments Active
POAI FAQ — answered by Alphio AI
Axe Compute Inc., formerly Predictive Oncology Inc., is engaged in using artificial intelligence (AI) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy when a tumor sample responds to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Through AI, it uses its proprietary biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of drug development. The Company offers a suite of solutions for oncology drug development from early discovery to clinical trials. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.